SUNNYVALE, Calif., April 26, 2012 – Accuray Incorporated (Nasdaq: ARAY), the premier radiation oncology company, announced today the launch of the Prostate Advances in Comparative Evidence (PACE) Study, an international, multi-center, randomized study to compare CyberKnife® Stereotactic Body Radiation Therapy (SBRT), da Vinci assisted and manual laparoscopic surgery and conventionally fractionated intensity modulated radiation therapy (IMRT), for the treatment of localized prostate cancer. The PACE Study aims to build upon the strong foundation of published evidence for CyberKnife prostate SBRT by creating comparative evidence to support its future potential as the gold standard in the treatment of organ confined prostate cancer. This information will enable clinicians and patients to make informed treatment decisions based on the highest level of clinical evidence.
Currently, there is no clear gold standard for localized prostate cancer treatment. A lack of comparative clinical data has prevented definitive conclusions to be drawn as to which therapy can be considered the preferred treatment for localized prostate cancer. Treatment decisions have often been made based on historical experience, aged comparisons of older treatment techniques or single modality experiences. Physicians and leading industry groups, including The Agency for Healthcare Quality and Research (AHRQ) and the Medicare Evidence Development and Coverage Advisory Committee (MEDCAC), have called for a randomized study comparing the most popular treatment options to bring clarity to the treatment landscape.
source; Accuray
No comments:
Post a Comment